VANBRUGH GROUP PRACTICE
LEVEL 2, GREENWICH CENTRE, 12 LAMBARDE SQUARE, LONDON
HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2010 | 9 | 15 | 60.0% | |
| HF 4 | 2011 | 8 | 9 | 88.9% | |
| HF 4 | 2012 | 8 | 9 | 88.9% | |
| HF 4 | 2013 | 8 | 9 | 88.9% | |
| HF004 | 2014 | 10 | 11 | 90.9% | |
| HF004 | 2015 | 9 | 10 | 90.0% | |
| HF004 | 2016 | 11 | 11 | 100.0% | |
| HF004 | 2017 | 12 | 13 | 92.3% | |
| HF004 | 2018 | 9 | 11 | 81.8% | |
| HF004 | 2019 | 10 | 13 | 76.9% | |
| HF004 | 2020 | 8 | 10 | 80.0% | |
| HF006 | 2021 | 10 | 10 | 100.0% | |
| HF006 | 2022 | 8 | 8 | 100.0% | |
| HF006 | 2023 | 15 | 15 | 100.0% |
